Objectives: To assess the global status of cervical cancer prevention and control through availability of best buys packages service, population coverage and policy cohesion. Methods: The 2017 WHO Country Capacity Survey contains responses from the 194 member states. Aspects of this survey address noncommunicable diseases (NCDs) and cancer control plans, registries, primary prevention, screening, treatment and palliative care, all pillars involved in the prevention and control of cervical cancer. All analyses were conducted in STATA 13. Results: 1. Service availability: HPV vaccination exists in 53% of countries but only 24% of countries have at least 50% population coverage. Cervical screening is offered in 76% of countries but population coverage is 50% or below in 30% of countries. Only 21% of countries were able to provide the NCD best buy package encompassing primary and secondary prevention, diagnosis, treatment and palliation of cervical cancer. No low (LIC)- or lower-middle income countries (LMIC) provide this complete package of services; radiation was the most common service to be missing,. A primary care package of services relevant to cervical cancer was provided in 20% of countries but no LIC provided this package; the most common missing service was early detection. In 58% of countries there were cancer treatment guidelines and they had access to all treatment modalities (surgery, radiation, and chemotherapy). Among countries reporting cervical cancer screening, 18% reported absence of treatment availability after screening. Similarly, 40% of countries reported no access to palliative care. 2. Service coverage: Only 40% of countries had both cervical cancer screening and HPV vaccination coverage of more than 70%. In 25% of countries screening coverage was low but vaccination rates covered 10-50% of the population (a clear policy choice of one strategy over another). 3. Policy cohesion: Screening implies both identification of pre and cancerous conditions. Thus any guideline for screening must ensure a strategy for treatment of cancer. Treatment and palliative care services were missing in 13% and 52% of the countries respective. While cervical cancer screening for women aged 30-49 is recommended as a best buy, reported initial age of national cervical caner screening programmes varied from 14-40 years. Conclusion: When resources are limited, implementation of cervical cancer care should involve a step wise approach of having treatment and palliative care available prior to implementing screening. As we report, national strategies for cervical cancer control need to navigate opportunities to optimize step-wise implementation, as well as optimize coverage and age-appropriate screening to improve efficiency.